12:00 AM
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xiaflex: Phase IIIb data

The open-label, international Phase IIIb AUX-CC-867 trial in 715 Dupuytren's contracture patients showed that 2 concurrent injections of 0.58 mg Xiaflex into palpable cords of 2 affected joints in the same hand followed by finger extension reduced total average fixed flexion contracture by 74.4% and improved total range of motion by a combined average of 66.6 degrees. Additionally, Xiaflex improved hand functionality as measured by average Unite Rhumatologique des Affections de la Main (URAM) scale score by 12.3 points. Auxilium said the estimated clinically important change in URAM scale score is 2.9 points. The company also...

Read the full 459 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >